Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis - Poll - MDSpire

Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis

  • By

  • Paul G. Kemps

  • Jennifer L. Picarsic

  • Sébastien Héritier

  • Jean Donadieu

  • Julien Haroche

  • Laure Farnault

  • Stefania Gaspari

  • Dmitry A. Evseev

  • Daria S. Osipova

  • Alexander E. Druy

  • Milen Minkov

  • Susan Picton

  • Andreas Beilken

  • Robert Möhle

  • Miloš B. Kuzmanović

  • Hitomi S. Okuma

  • Chung W. Chow

  • Martin A. Campbell

  • Gregory S. Phillips

  • Yuhang Zhou

  • Gaurav Goyal

  • Ronald S. Go

  • Kee Kiat Yeo

  • Bryan A. Sisk

  • Joanna L. Weinstein

  • Patrick K. Campbell

  • Eli L. Diamond

  • Jean-François Emile

  • April 14, 2026

  • 0 min

Share

Original Source(s)

Sustained remission after discontinuation of ALK inhibition in ALK-positive histiocytosis

  • by Paul G. Kemps, Jennifer L. Picarsic, Sébastien Héritier, Jean Donadieu, Julien Haroche, Laure Farnault, Stefania Gaspari, Dmitry A. Evseev, Daria S. Osipova, Alexander E. Druy, Milen Minkov, Susan Picton, Andreas Beilken, Robert Möhle, Miloš B. Kuzmanović, Hitomi S. Okuma, Chung W. Chow, Martin A. Campbell, Gregory S. Phillips, Yuhang Zhou, Gaurav Goyal, Ronald S. Go, Kee Kiat Yeo, Bryan A. Sisk, Joanna L. Weinstein, Patrick K. Campbell, Eli L. Diamond, Jean-François Emile

  • April 14, 2026

Related Content

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.

Novel PTRH2::ALK Fusion in ALK-positive Histiocytosis Presenting as a Liver Abscess in an Infant: A Case Study

Glutathione peroxidase 2 expression in human tumors: a tissue microarray study on 18,555 tumors